Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease

Cholinergic transmission loss is one of the major features in Alzheimer's Disease (AD). Acetylcholinesterase inhibitors (AChEI) are moderately active in AD. α7nAChR (alpha-7 nicotinic acetylcholine receptor), encoded by CHRNA7 (Nicotinic Cholinergic Receptor Alpha-7 gene), is involved in th...

Full description

Saved in:

Bibliographic Details
Published in:	Current drug targets Vol. 18; no. 10; p. 1179
Main Authors:	Russo, Patrizia, Kisialiou, Aliaksei, Moroni, Rossana, Prinzi, Giulia, Fini, Massimo
Format:	Journal Article
Language:	English
Published:	United Arab Emirates 01-01-2017
Subjects:	alpha7 Nicotinic Acetylcholine Receptor - genetics Alzheimer Disease - drug therapy Alzheimer Disease - genetics Cholinesterase Inhibitors - pharmacology Cholinesterase Inhibitors - therapeutic use Female Galantamine - pharmacology Galantamine - therapeutic use Gene Expression Regulation - drug effects Humans Indans - pharmacology Indans - therapeutic use Male Pharmacogenomic Variants Piperidines - pharmacology Piperidines - therapeutic use Polymorphism, Single Nucleotide Treatment Outcome Up-Regulation Acetylcholinesterase inhibitors (AChEI) CHRNA7 AChEI-cognitive response donepezil AD pathogenesis cholinergic transmission galantamine genetic polymorphisms (SNPs)
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!